Articles from Be Biopharma, Inc.

Be Biopharma, Inc. (“Be Bio”), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today presented results from new preclinical research demonstrating a single administration of BE-102, a BCM for the potential treatment for Hypophosphatasia (HPP), produces continuous levels of active ALP long-term in vivo. The findings will be presented during an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting on Saturday, May 17, at 10:45 AM CT.

Be Biopharma, Inc. (“Be Bio”), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting being held in New Orleans, May 13-17, 2025.

Be Biopharma, Inc. (“Be Bio”), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced the appointment of Susan Abu-Absi, Ph.D., as Chief Operating Officer. With over 20 years of experience in strategic operations, product development and manufacturing in the biotechnology industry, Dr. Abu-Absi brings a wealth of knowledge and expertise to the role, positioning Be Bio for continued growth and operational excellence.

Be Biopharma, Inc. (“Be Bio”), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced the publication in the journal Molecular Therapy of a manuscript highlighting first-of-its-kind preclinical research from a collaboration study showing homing and engraftment of ex-vivo-generated plasma cells in non-human primates (NHPs) with intact immune systems. The study highlights the ability of these plasma cells to engraft in NHPs without preconditioning, validating a crucial aspect of the BCM platform designed to develop innovative programs with best-in-class profiles. The study was funded and conducted through a collaborative research and development agreement with the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

Be Biopharma, Inc. (“Be Bio” or “the Company”), a leader in B Cell Medicines (BCMs), today announced the closing of its $92M Series C financing. The round includes participation from new investor Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, and Takeda Ventures, among others. In conjunction with the financing, Melissa McCracken, Ph.D. of Nextech will join Be Bio’s Board of Directors.

Be Biopharma, Inc. (“Be Bio”), a clinical-stage company pioneering engineered B Cell Medicines (BCMs), today announced that Chief Executive Officer Joanne Smith-Farrell, Ph.D. will present at the 43rd Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis in San Francisco, CA on Wednesday, January 15, 2025, at 3:30 pm PT.

Be Biopharma, Inc. (“Be Bio”), a clinical-stage company pioneering engineered B Cell Medicines (BCMs), today announced two key updates at the 66th ASH Annual Meeting in San Diego, CA. These updates include a Trial in Progress poster detailing the BeCoMe-9 clinical trial and an oral presentation highlighting the potential of Be Bio's BCM platform to create innovative programs with best-in-class profiles.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced that an abstract relating to its BCM platform has been accepted for oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego, California from December 7 to 10, 2024. In addition, a Trials in Progress abstract related to the BeCoMe-9 Phase 1/2 clinical trial for BE-101 in hemophilia B has been accepted for online publication. Both abstracts were published today and are now available on the ASH website at www.hematology.org.

Be Biopharma, Inc. (“Be Bio” or “the Company”), a leader in the discovery and development of engineered B Cell Medicines (BCMs), today announced key milestones alongside a new round of funding as its lead program, BE-101 for Hemophilia B, enters the clinic, and its second development candidate for Hypophosphatasia is unveiled. Both programs are built on Be Bio’s powerful and efficient BCM platform, which utilizes gene editing to engineer B cells to produce sustained levels of therapeutic proteins, resulting in durable, titratable, and redosable candidates that require no preconditioning and have the potential to become best-in-class genetic medicines.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced the presentation of preclinical data demonstrating the transformative power of BCMs to produce active alkaline phosphatase (ALP), highlighting BCMs as a potential treatment for Hypophosphatasia (HPP). Researchers coupled CRISPR/Cas9 precision gene engineering and artificial intelligence-guided protein design to modify primary human B cells to express ALP, an enzyme deficient in people living with HPP. The findings were presented during poster presentations at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting (Thursday September 26th through Saturday, September 28th).

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BE-101, a novel engineered B Cell medicine (BCM) being developed for the treatment of Hemophilia B. Be Bio is on track to initiate its Phase 1/2 study, BeCoMe-9, evaluating BE-101 in adults with severe or moderately severe Hemophilia B in the second half of 2024.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced the clearance of its Investigational New Drug application (IND) from the U.S. Food and Drug Administration (FDA) for BE-101, a first-in-class BCM in development for the potential treatment of hemophilia B. The Phase 1/2 clinical trial, BeCoMe-9, is a multi-center, first-in-human dose escalation study designed to assess the safety and preliminary efficacy of BE-101 in adult participants with moderately severe to severe hemophilia B. Be Bio expects to begin dosing participants in the second half of 2024.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced the addition of Paula Cannon, Ph.D., to its Scientific Advisory Board. Dr. Cannon, Distinguished Professor of Molecular Microbiology and Immunology at the Keck School of Medicine of the University of Southern California, was recently appointed President of the American Society for Gene and Cell Therapy (ASGCT). Dr. Cannon will work with other members of the Scientific Advisory Board to provide scientific and clinical guidance as the Company advances its pipeline of B Cell Medicine (BCM) programs, including its lead program, BE-101, a first-in-class BCM for the treatment of hemophilia B.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today presented results from new preclinical research demonstrating production of active ALP by a BCM, which highlights BCMs as a potential treatment for Hypophosphatasia (HPP). Researchers used CRISPR/Cas9 precision gene engineering and artificial intelligence-guided protein design to modify primary human B cells to produce ALP, an enzyme deficient in people living with HPP. The findings were presented during a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting on Friday, May 10, at 12:00pm ET.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, MD.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced that it will present at the 20th Annual WORLDSymposium™ being held February 4-9, 2024, in San Diego, California.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced the appointment of Angus Smith as Chief Financial Officer (CFO) and Wing-Yen Wong, M.D., as interim Chief Medical Officer (CMO).

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced that Chief Executive Officer Joanne Smith-Farrell,Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis in San Francisco, CA on Wednesday, January 10, 2024.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced results from a new preclinical study demonstrating that the company’s novel engineered BCM, BE-101, produces active and sustained levels of Factor IX (FIX) for the treatment of hemophilia B.​ These data were shared during an oral presentation at the 65th annual meeting of the American Society of Hematology taking place in San Diego, California. Also today, Be Bio announced plans to advance BE-101 as its lead program for the treatment of people with severe or moderately severe hemophilia B.​

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BeCMs), today announced that Chief Executive Officer Joanne Smith-Farrell, Ph.D., will present at the 35th Annual Piper Sandler Healthcare Conference being held at the Lotte New York Palace in New York, NY on Thursday, November 30, 2023.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs) today announced that it will present new preclinical data in an oral presentation at the 65th Annual Meeting of the American Society of Hematology (ASH) taking place December 9-12, 2023, in San Diego, California. The research will describe the development of an ex vivo precision-engineered B Cell Medicine (BCM) that produces active and sustained levels of factor IX (FIX). The abstract is now available online in a special issue of the ASH official journal, Blood.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), will present preclinical data demonstrating that a BCM-derived biologic can deliver steady-state plasma concentrations of a bispecific T cell engager at clinically relevant doses for treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). Findings from the study, conducted jointly with researchers at Seattle Children’s Research Institute, will be presented during the Society for Immunotherapy of Cancer’s 38th Annual Meeting.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), will present research from preclinical studies during the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Meeting. In an oral presentation on Friday, October 27, from 11:00 to 13:00 CEST, Be Bio demonstrates that BCMs are capable of producing a variety of therapeutic protein classes using precision gene editing. The data include durable in vivo production of the human clotting factor IX, prevention of tumor growth in a patient-derived xenograft model via a CD19xCD3 bispecific antibody, and engraftment without preconditioning in immunocompetent non-human primates (NHPs). Also being presented are findings from a preclinical study showing BCMs are capable of producing highly active acid sphingomyelinase, the gene defective in Niemann-Pick disease, and correct the disease phenotype in knockout cells.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BeCMs), today announced that Chief Executive Officer Joanne Smith-Farrell, Ph.D., will present at the annual Cell & Gene Meeting on the Mesa to be held October 10-12 in Carlsbad, California, and livestreamed globally.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BeCMs), today announced that Chief Executive Officer, Joanne Smith-Farrell, Ph.D., will present at the Jefferies Healthcare Conference being held in New York, NY, June 7-9, 2023. Company management will also be available for one-on-one meetings.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BeCMs), will present first-of-its-kind preclinical research today from a collaboration study showing homing and engraftment of B cells in non-human primates (NHPs) with intact immune systems. The findings will be presented during a late-breaking oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting from 9:30-9:45 a.m. PST. The study was funded and conducted through a collaborative research and development agreement with the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BeCMs), will present preclinical research today showing the precise genome engineering of human B cells to express diverse therapeutic proteins using the company’s proprietary platform. The findings will be presented during an oral session at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting at 2:15-2:30 p.m. PST with additional data in poster presentation 1453 on Friday, May 19th from 12:00-2:00 p.m. PST.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BeCMs), announced that it will present new data from preclinical research and collaboration programs at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting taking place May 16-20, 2023, in Los Angeles, Calif.